Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Dec 21, 2025, 02:55Epigenetic Links Between Paternal Age, Reproduction and Offspring Health – Reproduction and Fertility
-
Dec 21, 2025, 02:43Medicines and Pregnancy: ANSM Proposes New Labeling – B’RIGHT
-
Dec 21, 2025, 02:28Steven Palter: It is time to retire the out of date ‘2 week wait’ for pregnancy tests after IVF
-
Dec 21, 2025, 02:15Siddhartha Yadav: New ASCO Guideline for Managing Cancer During Pregnancy
-
Dec 21, 2025, 01:56New Patient Resource on Thyroid Issues in Pregnancy – RCOG
-
Dec 21, 2025, 01:49CDC Releases 2024 Pregnancy Mortality Data – Preeclampsia Foundation
-
Dec 21, 2025, 01:30Caitlin Wyrwoll: New Insights on Maternal Health and Extreme Heat
-
Dec 20, 2025, 10:57Clare Pin-Chia Huang: New Research Links Maternal Diabetes to Pregnancy Risks
-
Dec 20, 2025, 10:53Evaluating Maternal and Neonatal Health in Rheumatoid Arthritis Pregnancies – Hiroki Ozawa